This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 25, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced initiation of Factual Stock Report coverage in conjunction with Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have corporate information disseminated to users of Standard & Poor's MarketScope Advisor, used by more than 100,000 investment advisors.
Starting with today's attached first Factual Stock Report, Standard and Poor's will make available a weekly updated Factual Stock Report on NORTHWEST BIO initiatives and strategy, as well as basic stock-related and financial information. Starting today, these Factual Stock Reports will be available through the NORTHWEST BIO website at
www.nwbio.com and the MarketScope Advisor public website link at
This first Report notes that, "When compared to other active immune therapy companies in the expanding cancer immune space, NWBO believes their DCVax technology is more effective, longer lasting, easier to administer, can be less costly, and can potentially apply to all patients with the target cancers, while certain other companies' treatments can only apply to a limited portion of the patient population and require screening of patients to determine which of them can be treated. In addition, NWBO has a deeper product pipeline, with multiple product lines and multiple target cancers already cleared for clinical trials by FDA. NWBO is unique in pursuing
Europe in parallel with the US, for both its clinical trials and its manufacturing."
Linda Powers, CEO of NORTHWEST BIO, commented that, "It is important to our accelerating GBM brain cancer clinical trial program in both the US and
Europe, that a financial organization of the significance of S&P is now following us and helping spread the word of our potential advantages as to cost, effectiveness, manufacturing, applicability to a larger patient population, and simplicity of delivery and administration. We welcome the increased attention as we work ever harder to bring the promise of DCVax to the global market."
The first step under this comprehensive S&P program was taken several weeks ago with the listing of NORTHWEST BIO in the Daily News section of S&P's Standard Corporation Records, a recognized manual for secondary trading in most states under their Blue Sky Laws.